SAN DIEGO and VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Sophiris Bio
Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a
biopharmaceutical company studying topsalysin (PRX302), a
first-in-class, pore-forming protein, in late-stage clinical trials
for the treatment of patients with urological diseases, today
announced that Randall E. Woods, president and chief executive
officer, will present at two upcoming healthcare-focused investor
conferences. On Monday, April 8,
2019, Mr. Woods will present a corporate overview at the
H.C. Wainwright Global Life Sciences Conference at 12:10 pm BST in London, England. On Wednesday, April 10, 2019, Mr. Woods will present
a corporate overview at the 18th Annual Needham
Healthcare Conference at 2:50 pm EDT
in New York, NY.
The presentations will be webcast live and can be accessed
through the Investor Relations page at www.sophirisbio.com.
Replays of the presentations will be available on the Company's
website for 90 days.
About Sophiris
Sophiris Bio Inc. is a late-stage clinical biopharmaceutical
company developing topsalysin (PRX302) for the treatment of
patients with urological diseases. Topsalysin has completed Phase 2
clinical development for the focal treatment of localized prostate
cancer and is in Phase 3 clinical development for the treatment of
the lower urinary tract symptoms of benign prostatic hyperplasia
(BPH). Topsalysin is a highly potent ablative agent that is
selective and targeted in that it is only activated by
enzymatically active PSA which is found in high concentrations in
the transition zone of the prostate and in and around prostate
tumor cells. For more information, please visit
www.sophirisbio.com.
Certain statements included in this press release may be
considered forward-looking. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on
Sophiris' current beliefs as well as assumptions made by and
information currently available to Sophiris and relate to, among
other things, anticipated financial performance, business
prospects, strategies, regulatory developments, market acceptance
and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by Sophiris in its
public securities filings; actual events may differ materially from
current expectations. Sophiris disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Company Contact:
Peter
Slover
Chief Financial Officer
(858) 777-1760
Corporate Communications and Media
Contact:
Jason
Spark
Canale
Communications
(619)
849-6005
jason@canalecomm.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sophiris-bio-to-present-at-two-upcoming-investor-conferences-300823226.html
SOURCE Sophiris Bio Inc.